Vinci Pharmaceuticals closes more than $8 million Series A

Vinci Pharmaceuticals said it closed an $8+ million Series A financing to support GMP manufacturing, testing and release activities for EPIPLANT and first-in-human studies. The company also said it plans a Phase 1/2a clinical study in 2027.